Instil Bio (TIL) Competitors $27.99 +2.05 (+7.90%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$27.53 -0.46 (-1.66%) As of 08/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TIL vs. PHAT, KROS, RLAY, BCAX, TLRY, ORGO, XNCR, MRVI, TSHA, and TRMLShould you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Phathom Pharmaceuticals (PHAT), Keros Therapeutics (KROS), Relay Therapeutics (RLAY), Bicara Therapeutics (BCAX), Tilray Brands (TLRY), Organogenesis (ORGO), Xencor (XNCR), Maravai LifeSciences (MRVI), Taysha Gene Therapies (TSHA), and Tourmaline Bio (TRML). These companies are all part of the "pharmaceutical products" industry. Instil Bio vs. Its Competitors Phathom Pharmaceuticals Keros Therapeutics Relay Therapeutics Bicara Therapeutics Tilray Brands Organogenesis Xencor Maravai LifeSciences Taysha Gene Therapies Tourmaline Bio Instil Bio (NASDAQ:TIL) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability. Do analysts prefer TIL or PHAT? Instil Bio presently has a consensus price target of $119.00, indicating a potential upside of 325.15%. Phathom Pharmaceuticals has a consensus price target of $17.50, indicating a potential upside of 79.67%. Given Instil Bio's higher probable upside, analysts clearly believe Instil Bio is more favorable than Phathom Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is TIL or PHAT more profitable? Instil Bio has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -289.51%. Phathom Pharmaceuticals' return on equity of 0.00% beat Instil Bio's return on equity.Company Net Margins Return on Equity Return on Assets Instil BioN/A -45.52% -29.23% Phathom Pharmaceuticals -289.51%N/A -83.82% Which has higher earnings & valuation, TIL or PHAT? Instil Bio has higher earnings, but lower revenue than Phathom Pharmaceuticals. Instil Bio is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInstil BioN/AN/A-$74.14M-$11.97-2.34Phathom Pharmaceuticals$55.25M12.31-$334.33M-$5.24-1.86 Which has more volatility & risk, TIL or PHAT? Instil Bio has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Does the media prefer TIL or PHAT? In the previous week, Phathom Pharmaceuticals had 13 more articles in the media than Instil Bio. MarketBeat recorded 13 mentions for Phathom Pharmaceuticals and 0 mentions for Instil Bio. Instil Bio's average media sentiment score of 0.00 beat Phathom Pharmaceuticals' score of -0.06 indicating that Instil Bio is being referred to more favorably in the media. Company Overall Sentiment Instil Bio Neutral Phathom Pharmaceuticals Neutral Do insiders & institutionals believe in TIL or PHAT? 60.6% of Instil Bio shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 47.2% of Instil Bio shares are held by insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryInstil Bio and Phathom Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get Instil Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TIL vs. The Competition Export to ExcelMetricInstil BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$183.55M$2.99B$5.51B$9.72BDividend YieldN/A2.45%4.60%4.12%P/E Ratio-2.3417.2130.0324.75Price / SalesN/A311.98450.3797.61Price / CashN/A41.7736.7758.47Price / Book1.087.318.185.59Net Income-$74.14M-$54.43M$3.26B$265.99M7 Day Performance25.91%0.01%6.13%5.07%1 Month Performance4.60%0.63%0.07%0.61%1 Year Performance159.16%8.41%36.31%22.83% Instil Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TILInstil Bio2.1537 of 5 stars$27.99+7.9%$119.00+325.2%+159.2%$183.55MN/A-2.34410Upcoming EarningsPHATPhathom Pharmaceuticals3.1184 of 5 stars$8.64+3.5%$17.50+102.5%-17.1%$582.95M$55.25M-1.65110News CoverageGap UpKROSKeros Therapeutics2.6771 of 5 stars$14.62+2.1%$30.56+109.0%-69.7%$581.61M$3.55M-81.22100News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionRLAYRelay Therapeutics1.9762 of 5 stars$3.65+8.6%$17.67+384.0%-51.9%$576.05M$10.01M-1.64330News CoveragePositive NewsEarnings ReportAnalyst ForecastBCAXBicara Therapeutics2.2117 of 5 stars$11.12+5.6%$31.86+186.5%N/A$574.27MN/A0.0032News CoveragePositive NewsUpcoming EarningsTLRYTilray Brands3.0477 of 5 stars$0.61+6.9%$1.92+215.3%-63.8%$572.39M$821.31M-0.262,650Options VolumeORGOOrganogenesis4.3041 of 5 stars$4.60+2.0%$6.50+41.3%+78.4%$572.11M$482.04M-27.06950News CoverageEarnings ReportAnalyst ForecastXNCRXencor3.4821 of 5 stars$7.95-0.4%$28.00+252.2%-54.9%$567.94M$110.49M-2.60280News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionMRVIMaravai LifeSciences3.6119 of 5 stars$2.27+2.3%$6.64+192.5%-74.2%$565.34M$259.18M-1.99610News CoverageUpcoming EarningsOptions VolumeGap DownTSHATaysha Gene Therapies3.1532 of 5 stars$2.71+3.0%$8.17+201.4%+30.1%$564.56M$8.33M-7.97180Upcoming EarningsTRMLTourmaline Bio1.8772 of 5 stars$21.59-0.8%$49.33+128.5%+48.3%$558.91MN/A-6.7344News CoverageUpcoming Earnings Related Companies and Tools Related Companies PHAT Competitors KROS Competitors RLAY Competitors BCAX Competitors TLRY Competitors ORGO Competitors XNCR Competitors MRVI Competitors TSHA Competitors TRML Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TIL) was last updated on 8/10/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instil Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Instil Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TIL Stock Alerts